uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

Company Performance - uniQure reported a quarterly loss of $0.69 per share, better than the Zacks Consensus Estimate of a loss of $0.89, and an improvement from a loss of $1.16 per share a year ago, resulting in an earnings surprise of +22.47% [1] - The company posted revenues of $5.26 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 26.23%, and down from $11.13 million in the same quarter last year [2] - Over the last four quarters, uniQure has surpassed consensus EPS estimates three times but has not beaten consensus revenue estimates [2] Stock Outlook - The stock has lost about 15.2% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The current consensus EPS estimate for the coming quarter is -$0.91 on revenues of $5.97 million, and for the current fiscal year, it is -$3.34 on revenues of $37.66 million [7] - The estimate revisions trend for uniQure was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which uniQure belongs, is currently in the top 38% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]